These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 36634582)

  • 21. Independent risk factors for myasthenic crisis and disease exacerbation in a retrospective cohort of myasthenia gravis patients.
    Nelke C; Stascheit F; Eckert C; Pawlitzki M; Schroeter CB; Huntemann N; Mergenthaler P; Arat E; Öztürk M; Foell D; Schreiber S; Vielhaber S; Gassa A; Stetefeld H; Schroeter M; Berger B; Totzeck A; Hagenacker T; Meuth SG; Meisel A; Wiendl H; Ruck T
    J Neuroinflammation; 2022 Apr; 19(1):89. PubMed ID: 35413850
    [TBL] [Abstract][Full Text] [Related]  

  • 22. IVIG Versus PLEX in the Treatment of Worsening Myasthenia Gravis: What is the Evidence?: A Critically Appraised Topic.
    Dhawan PS; Goodman BP; Harper CM; Bosch PE; Hoffman-Snyder CR; Wellik KE; Wingerchuk DM; Demaerschalk BM
    Neurologist; 2015 May; 19(5):145-8. PubMed ID: 25970838
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intravenous immunoglobulin as monotherapy for myasthenia gravis during pregnancy.
    Gamez J; Salvado M; Casellas M; Manrique S; Castillo F
    J Neurol Sci; 2017 Dec; 383():118-122. PubMed ID: 29246598
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A retrospective observational study on characteristics, treatment patterns, and healthcare resource use of patients with myasthenia gravis in England.
    van Enkhuizen J; Binns J; Betts A; Hosnijeh FS; Alexander M; McCormack M; Jacob S
    Ther Adv Neurol Disord; 2024; 17():17562864241237495. PubMed ID: 38634003
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Direct and Indirect Healthcare Resource Utilization and Costs Among Migraine Patients in the United States.
    Bonafede M; Sapra S; Shah N; Tepper S; Cappell K; Desai P
    Headache; 2018 May; 58(5):700-714. PubMed ID: 29446063
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Subcutaneous Immunoglobulin Therapy in the Chronic Management of Myasthenia Gravis: A Retrospective Cohort Study.
    Bourque PR; Pringle CE; Cameron W; Cowan J; Chardon JW
    PLoS One; 2016; 11(8):e0159993. PubMed ID: 27490101
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chronic immunoglobulin maintenance therapy in myasthenia gravis.
    Alcantara M; Sarpong E; Barnett C; Katzberg H; Bril V
    Eur J Neurol; 2021 Feb; 28(2):639-646. PubMed ID: 32964565
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of myasthenia gravis acute exacerbations with intravenous immunoglobulin.
    Gajdos P; Chevret S
    Ann N Y Acad Sci; 2008; 1132():271-5. PubMed ID: 18096850
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Physician- and patient-reported perspectives on myasthenia gravis in Europe: a real-world survey.
    Mahic M; Bozorg A; DeCourcy J; Golden K; Gibson G; Taylor C; Scowcroft A
    Orphanet J Rare Dis; 2023 Jun; 18(1):169. PubMed ID: 37386469
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intravenous immunoglobulin maintenance treatment in myasthenia gravis: a randomized, controlled trial sample size simulation.
    Eienbröker C; Seitz F; Spengler A; Kurz H; Seipelt M; Sommer N; Oertel WH; Timmesfeld N; Tackenberg B
    Muscle Nerve; 2014 Dec; 50(6):999-1004. PubMed ID: 24710856
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intravenous immunoglobulin as treatment for myasthenia gravis: current evidence and outcomes.
    Alabdali M; Barnett C; Katzberg H; Breiner A; Bril V
    Expert Rev Clin Immunol; 2014 Dec; 10(12):1659-65. PubMed ID: 25331319
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical and economic burden of obstructive hypertrophic cardiomyopathy in the United States.
    Jain SS; Li SS; Xie J; Sutton MB; Fine JT; Edelberg JM; Gao W; Spertus JA; Cohen DJ
    J Med Econ; 2021; 24(1):1115-1123. PubMed ID: 34493144
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Healthcare Resource Utilization and Costs of Steroid-Associated Complications in Patients With Graft-Versus-Host Disease.
    Bell EJ; Yu J; Bhatt V; Bunner SH; Lal LS; Galvin J; Weisdorf D
    Transplant Cell Ther; 2022 Oct; 28(10):707.e1-707.e7. PubMed ID: 35483620
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Healthcare resource use in myasthenia gravis: a US health claims analysis.
    Mahic M; Bozorg A; Rudnik J; Zaremba P; Scowcroft A
    Ther Adv Neurol Disord; 2023; 16():17562864221150327. PubMed ID: 36710723
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Healthcare resource utilization by patients with treatment-refractory myasthenia gravis in England.
    Harris L; Graham S; MacLachlan S; Exuzides A; Jacob S
    J Med Econ; 2019 Jul; 22(7):691-697. PubMed ID: 30841772
    [No Abstract]   [Full Text] [Related]  

  • 36. Alopecia Areata Treatment Patterns, Healthcare Resource Utilization, and Comorbidities in the US Population Using Insurance Claims.
    Senna M; Ko J; Tosti A; Edson-Heredia E; Fenske DC; Ellinwood AK; Rueda MJ; Zhu B; King B
    Adv Ther; 2021 Sep; 38(9):4646-4658. PubMed ID: 34292518
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of myasthenia gravis exacerbation with intravenous immunoglobulin: a randomized double-blind clinical trial.
    Gajdos P; Tranchant C; Clair B; Bolgert F; Eymard B; Stojkovic T; Attarian S; Chevret S;
    Arch Neurol; 2005 Nov; 62(11):1689-93. PubMed ID: 16286541
    [TBL] [Abstract][Full Text] [Related]  

  • 38. IVIg in myasthenia gravis, Lambert Eaton myasthenic syndrome and inflammatory myopathies: current status.
    Illa I
    J Neurol; 2005 May; 252 Suppl 1():I14-8. PubMed ID: 15959667
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Economic burden in patients with ALK + non-small cell lung cancer, with or without brain metastases, receiving second-line anaplastic lymphoma kinase (ALK) inhibitors.
    Lin HM; Pan X; Hou P; Huang H; Wu Y; Ren K; Jahanzeb M
    J Med Econ; 2020 Aug; 23(8):894-901. PubMed ID: 32347754
    [No Abstract]   [Full Text] [Related]  

  • 40. Plasma exchange versus intravenous immunoglobulin for myasthenia gravis crisis: an acute hospital cost comparison study.
    Heatwole C; Johnson N; Holloway R; Noyes K
    J Clin Neuromuscul Dis; 2011 Dec; 13(2):85-94. PubMed ID: 22361692
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.